<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7362761\results\search\drug\results.xml">
  <result pre="and TNFÎ±; (21)], a high serum aspartate aminotransferase (AST) or" exact="alanine" post="aminotransferase (ALT), procalcitonin and ferritin levels (21, 22), decreased"/>
  <result pre="MIP1, Macrophage Inflammatory Protein 1; MCP-1, monocyte chemotactic protein-1; ALT," exact="alanine" post="transaminase; AST, aspartate transaminase; CRP, C-reactive protein. Potential Therapeutic"/>
  <result pre="showed faster virus clearance in patients with COVID-19 who received" exact="hydroxychloroquine" post="(33). Initial dose: 600 mg (of chloroquine) followed by"/>
  <result pre="vitro study in a mouse model demonstrated the efficacy of" exact="camostat" post="in protecting mice from death from a lethal SARS-CoV"/>
  <result pre="that doses of 600 mg (200 mg, three times) of" exact="camostat" post="daily are expected to reduce SARS-CoV-2 infection; but human"/>
  <result pre="protease inhibitor used to treat HIV infection in combination with" exact="ritonavir" post="to increase its availability. Lopinavir has some degree of"/>
  <result pre="molecules that could inhibit ACE2 have been identified, of which" exact="ruxolitinib" post="is included in a clinical study together with mesenchymal"/>
  <result pre="of the complications of COVID-19 with frequent fatal consequences (42)." exact="Chloroquine" post="[(N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine)], a conventional drug for the treatment of malaria,"/>
  <result pre="applied in several studies against CoVs. In an early report," exact="chloroquine" post="was found to be effective in preventing the spread"/>
  <result pre="be effective in preventing the spread of SARS-CoV-2 in vitro." exact="Chloroquine" post="was assumed to elevate endosomal pH and to interfere"/>
  <result pre="of mild upper respiratory tract infections. Research findings showed that" exact="chloroquine" post="inhibits HCoV-OC43 replication in HRT-18 cells with LD50 effective"/>
  <result pre="Î¼M and an IC50 of 419 Î¼M (45). In addition," exact="chloroquine" post="(15 mg/kg) could prevent the HCoV-OC43-induced death in newborn"/>
  <result pre="rate (98.6%) of the pups (46). This report advocated that" exact="chloroquine" post="can be highly effective against HCoVs and it may"/>
  <result pre="the penetration of the virus into cellsâ€&quot;transmembrane proteinase TMPRSS2. The" exact="camostat" post="molecule, a synthetic serine protease inhibitor approved in Japan"/>
  <result pre="agent and is approved for the treatment of cystic fibrosis." exact="Nafamostat" post="has mucolytic action and can prevent the deterioration of"/>
  <result pre="/Ritonavir Combination The combination of lopinavir/ritonavir protease inhibitors (marketed as" exact="Kaletra" post="for the treatment of HIV infection), with or without"/>
  <result pre="addition to supportive treatment, the guide includes the use of" exact="lopinavir" post="+ ritonavir + IFN, which is, however, supported by"/>
  <result pre="supportive treatment, the guide includes the use of lopinavir +" exact="ritonavir" post="+ IFN, which is, however, supported by only a"/>
  <result pre="the two protease inhibitors are also administered in studies with" exact="ribavirin" post="(a guanosine analog and RNA synthesis inhibitor that could"/>
  <result pre="who are not pregnant (59). Neuraminidase Inhibitors Oseltamivir, peramivir, or" exact="zanamivir" post="are not justified for the treatment of COVID-19, because"/>
  <result pre="The combination of lopinavir/ritonavir protease inhibitors (marketed under the name" exact="Kaletra" post="for the treatment of HIV infection), with or without"/>
  <result pre="addition to supportive treatment, the guide includes the use of" exact="lopinavir" post="+ ritonavir + IFN, which is supported, however, by"/>
  <result pre="supportive treatment, the guide includes the use of lopinavir +" exact="ritonavir" post="+ IFN, which is supported, however, by only a"/>
  <result pre="protease inhibitors are administered in studies and in combination with" exact="ribavirin" post="(guanosine analog and RNA synthesis inhibitor, which within SARS-COV-2"/>
  <result pre="between lopinavir/ritonavir (with or without interferon beta), and remdesivir and" exact="chloroquine" post="(or hydroxychloroquine). Spain and Norway are the countries that"/>
  <result pre="evolution of the infection (71). To test the impact of" exact="camostat" post="mesilate on COVID-19 Infection (CamoCO-19), an Investigator-initiated Randomized, Placebo-controlled,"/>
  <result pre="be announced in December this year (72). The efficacy of" exact="nafamostat" post="in patients with Covid-19 (RACONA study), is the subject"/>
  <result pre="of the RACONA study is to test the hypothesis that" exact="nafamostat" post="is useful in the treatment of COVID-19 lung damage."/>
  <result pre="of the coagulation cascade, pulmonary embolism, and bacterial superinfections (73)." exact="Chloroquine" post="phosphate displayed apparent efficacy and acceptable safety against SARS-COV-2"/>
  <result pre="of the People's Republic of China. Another recent study suggested" exact="chloroquine" post="phosphate tablet (500 mg twice per day for 10"/>
  <result pre="twice per day for 10 days) against SARS-COV-2 (74). Although" exact="chloroquine" post="has long been used to treat malaria and amebiasis,"/>
  <result pre="developed widespread resistance to it (75). Furthermore, an overdose of" exact="chloroquine" post="was known to cause acute poisoning and death (76)"/>
  <result pre="and death (76) which limits its utilization in clinical practices." exact="Hydroxychloroquine" post="is a derivative of chloroquine, and significantly less (~40%)"/>
  <result pre="derivative of chloroquine, and significantly less (~40%) toxic (77). Recently," exact="hydroxychloroquine" post="was found to efficiently inhibit the SARS-CoV-2 infection in"/>
  <result pre="viral loads was evaluated using SARS-COV-2 patients from France (78)." exact="Hydroxychloroquine" post="(600 mg daily) was administered to patients and their"/>
  <result pre="significant reduction of the viral load. Interestingly, the addition of" exact="azithromycin" post="to hydroxychloroquine significantly eliminated the virus as compared to"/>
  <result pre="of the viral load. Interestingly, the addition of azithromycin to" exact="hydroxychloroquine" post="significantly eliminated the virus as compared to a single"/>
  <result pre="to a single therapy (79). This clinical survey demonstrated that" exact="hydroxychloroquine" post="treatment is significantly associated with viral load reduction in"/>
  <result pre="infected patients, with better results obtained by the addition of" exact="azithromycin" post="(78). This might be a milestone preventive option in"/>
  <result pre="useful in severe lung injury), and in the case of" exact="chloroquine" post="there is insufficient evidence to substantiate the studies. However,"/>
  <result pre="can bring about clinical improvements, such as statins, heparin, and" exact="vitamin C." post="In addition to the molecules described by WHO, recent"/>
  <result pre="extracts of plants and plant parts Gentiana scabra Bunge (the" exact="dried" post="rhizome), Dioscorea polystachya Turcz. (the tuber), Senna tora (L.)"/>
  <result pre="Dioscorea polystachya Turcz. (the tuber), Senna tora (L.) Roxb. (the" exact="dried" post="seed), Taxillus chinensis (DC.) Danser (the dried stem with"/>
  <result pre="(L.) Roxb. (the dried seed), Taxillus chinensis (DC.) Danser (the" exact="dried" post="stem with leaf), and Cibotium barometz (L.) J.Sm. (the"/>
  <result pre="dried stem with leaf), and Cibotium barometz (L.) J.Sm. (the" exact="dried" post="rhizome) were found to be potent inhibitors of SARS-CoV-2"/>
  <result pre="+RNA replication complexes. Viruses. (2015) 7:4385â€&quot;413. 10.3390/v708282526287230 12.FarsalinosKNiauraRLe HouezecJBarbouniATsatsakisAKouretasDet al.." exact="Nicotine" post="and SARS-CoV-2: COVID-19 may be a disease of the"/>
  <result pre="24.DoceaAOGofitÄƒECalinaDZaharieSValceaDIMitru?PAutoimmune disorders due to double antiviral therapy with Peginterferon and" exact="Ribavirin" post="in patients with hepatitis C virus infection. Farmacia J."/>
  <result pre="Biol. (2020) 12:322â€&quot;5. 10.1093/jmcb/mjaa01432236562 33.ChenJLiuDLiuLLiuPXuQXiaLet al.. [A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19]. Zhejiang Da"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="Dis. (2020) ciaa237. 10.1093/cid/ciaa237. [Epub ahead of print]. 44.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
  <result pre="Chem. (2020) 295:4773â€&quot;9. 10.1074/jbc.AC120.01305632094225 46.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.. Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn mice. Antimicrob"/>
  <result pre="vitro. Cell Discov. (2020) 6:16. 10.1038/s41421-020-0156-032194981 49.YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIet al.. Identification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
  <result pre="findings. Thorax. (2004) 59:252â€&quot;6. 10.1136/thorax.2003.01265814985565 55.YaoTTQianJDZhuWYWangYWangGQ. A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
  <result pre="https://clinicaltrials.gov/ (accessed April 10, 2020). 73.collab: University Hospital PadovaEfficacy of" exact="Nafamostat" post="in Covid-19 Patients (RACONA Study) (RACONA). NCT04352400 (2020). Available"/>
  <result pre="April 10, 2020). 74.collab: Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus[Expert consensus on chloroquine"/>
  <result pre="for Chloroquine in the Treatment of Novel Coronavirus[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua"/>
  <result pre="Cryptolepis, and Tabebuia genera. Phytother Res. (2020) 1â€&quot;14. 10.1002/ptr.662832022345 76.StokkermansTJGoyalABansalPTrichonasG." exact="Chloroquine" post="And Hydroxychloroquine Toxicity. In: StatPearls. Treasure Island: StatPearls Publishing"/>
  <result pre="Tabebuia genera. Phytother Res. (2020) 1â€&quot;14. 10.1002/ptr.662832022345 76.StokkermansTJGoyalABansalPTrichonasG. Chloroquine And" exact="Hydroxychloroquine" post="Toxicity. In: StatPearls. Treasure Island: StatPearls Publishing (2020). 77.McChesneyEW."/>
  <result pre="Island: StatPearls Publishing (2020). 77.McChesneyEW. Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfate. Am J Med. (1983) 75:11â€&quot;8. 10.1016/0002-9343(83)91265-26408923 78.GautretPLagierJ-CParolaPHoangVTMeddebLMailheMet al.."/>
  <result pre="hydroxychloroquine sulfate. Am J Med. (1983) 75:11â€&quot;8. 10.1016/0002-9343(83)91265-26408923 78.GautretPLagierJ-CParolaPHoangVTMeddebLMailheMet al.." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
  <result pre="Am J Med. (1983) 75:11â€&quot;8. 10.1016/0002-9343(83)91265-26408923 78.GautretPLagierJ-CParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="SARS-coronavirus. J Med Chem. (2005) 48:1256â€&quot;9. 10.1021/jm049300815715493 113.AmiciCDi CaroACiucciAChiappaLCastillettiCMartellaVet al.." exact="Indomethacin" post="has a potent antiviral activity against SARS coronavirus. Antivir"/>
 </snippets>
</snippetsTree>
